[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2023001688A - Metodos y composiciones para tratar el sindrome de ovario poliquistico. - Google Patents

Metodos y composiciones para tratar el sindrome de ovario poliquistico.

Info

Publication number
MX2023001688A
MX2023001688A MX2023001688A MX2023001688A MX2023001688A MX 2023001688 A MX2023001688 A MX 2023001688A MX 2023001688 A MX2023001688 A MX 2023001688A MX 2023001688 A MX2023001688 A MX 2023001688A MX 2023001688 A MX2023001688 A MX 2023001688A
Authority
MX
Mexico
Prior art keywords
pcos
compositions
polycystic ovary
ovary syndrome
methods
Prior art date
Application number
MX2023001688A
Other languages
English (en)
Inventor
David Karpf
Christopher Barnes
Mustafa Noor
Original Assignee
Spruce Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spruce Biosciences Inc filed Critical Spruce Biosciences Inc
Publication of MX2023001688A publication Critical patent/MX2023001688A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El síndrome de ovario poliquístico (PCOS) se caracteriza por niveles elevados de andrógenos, quistes en los ovarios, y períodos irregulares. Las mujeres con PCOS presentan síntomas adicionales, que incluyen hirsutismo, alopecia, acné, infertilidad, aumento de peso, fatiga, depresión, y cambios de humor. La presente divulgación proporciona nuevos compuestos, sales, composiciones y usos de los mismos en el tratamiento del PCOS debido a andrógenos suprarrenales elevados. Además, la presente divulgación proporciona métodos para tratar el PCOS debido a andrógenos suprarrenales elevados.
MX2023001688A 2020-08-12 2021-08-12 Metodos y composiciones para tratar el sindrome de ovario poliquistico. MX2023001688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063064863P 2020-08-12 2020-08-12
PCT/US2021/045780 WO2022036123A1 (en) 2020-08-12 2021-08-12 Methods and compositions for treating polycystic ovary syndrome

Publications (1)

Publication Number Publication Date
MX2023001688A true MX2023001688A (es) 2023-02-22

Family

ID=80248172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001688A MX2023001688A (es) 2020-08-12 2021-08-12 Metodos y composiciones para tratar el sindrome de ovario poliquistico.

Country Status (11)

Country Link
US (2) US12098152B2 (es)
EP (1) EP4175572A4 (es)
JP (1) JP2023537598A (es)
KR (2) KR20230043222A (es)
CN (1) CN116322544B (es)
AU (1) AU2021324839B2 (es)
BR (1) BR112023002497A2 (es)
CA (1) CA3188730A1 (es)
IL (1) IL300478A (es)
MX (1) MX2023001688A (es)
WO (1) WO2022036123A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110996943A (zh) 2017-08-14 2020-04-10 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
JP7238130B2 (ja) 2018-12-07 2023-03-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
WO2022036123A1 (en) 2020-08-12 2022-02-17 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DE69323768T2 (de) 1992-12-17 1999-07-01 Pfizer Inc., New York, N.Y. Pyrrolopyrimidine als crf antagonisten
CN1157620A (zh) * 1994-07-15 1997-08-20 纽罗克里恩生物科学有限公司 促肾上腺皮质素释放因子-结合蛋白抑制剂及其用途
HUP9900575A3 (en) 1996-02-07 2001-11-28 Neurocrine Biosciences Inc San Pyrazolopyrimidines as crf receptor antagonists
BR9710544A (pt) 1996-07-24 1999-08-17 Du Pont Pharm Co M-todo de tratamento composto e composi-Æo farmac-utica
HU228962B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo triazines, pharmaceutical compositions containing them and use of the compounds
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
WO1999038868A1 (en) 1998-01-28 1999-08-05 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
IL137019A (en) 1998-01-28 2010-11-30 Du Pont Pharm Co 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
JP2003510326A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション アミノ置換ピラゾロ［１，５−ａ］−１，５−ピリミジン類及びピラゾロ［１，５−ａ］−１，３，５−トリアジン類
BR0008059A (pt) 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
SK287603B6 (sk) 2001-03-13 2011-03-04 Bristol-Myers Squibb Pharma Company 4-(2-Butylamino)-2,7-dimetyl-8-(2-metyl-6-metoxypyrid-3- yl)pyrazol-[1,5-a]-1,3,5-triazín, farmaceutická kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny v terapii a na prípravu farmaceutickej kompozície a výrobok obsahujúci túto zlúčeninu
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
WO2004002965A1 (de) * 2002-06-29 2004-01-08 Zentaris Gmbh Aryl- und heteroarylcarbonylpiperazine und deren verwendung zur behandlung gutartiger und bösartiger tumorerkrankungen
US20050085479A1 (en) 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
EP2272514A1 (en) 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
RU2394035C2 (ru) 2003-12-22 2010-07-10 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Антагонисты crf-рецепторов и способы, относящиеся к ним
JP2007522200A (ja) 2004-02-13 2007-08-09 ファイザー・プロダクツ・インク 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ
EP1722826A2 (en) 2004-02-13 2006-11-22 SB Pharmco Puerto Rico Inc. Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006102194A1 (en) 2005-03-21 2006-09-28 Eli Lilly And Company Imidazopyridazine compounds
WO2007090087A2 (en) 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
MY146388A (en) * 2006-09-20 2012-08-15 Lilly Co Eli Thiazole pyrazolopyrimidines as crfi receptor antagonists
AU2007297481B2 (en) 2006-09-20 2012-03-08 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
DE102007002260A1 (de) * 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
PE20090142A1 (es) * 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
US8952207B2 (en) 2007-09-11 2015-02-10 The University Of Houston System Copper-catalyzed C—H bond arylation
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2010039678A1 (en) 2008-10-02 2010-04-08 Eli Lilly And Company Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
EP2384437B1 (en) 2008-12-24 2018-12-12 Quest Diagnostics Investments Incorporated Mass spectrometry assay for pregnenolone and 17-hydroxypregnenolone
US9750568B2 (en) * 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
EP2841068B8 (en) 2012-04-23 2019-03-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Crhr1 antagonists for use in the treatment of patients having crh overactivity
IL296683B2 (en) 2014-01-21 2023-12-01 Neurocrine Biosciences Inc Preparations for the treatment of congenital adrenal hyperplasia
EP3277191B1 (en) * 2015-03-31 2023-11-15 May Health US Inc. Methods and systems for the manipulation of ovarian tissues
JP6902682B2 (ja) * 2015-05-18 2021-07-14 カンディー セラピューティクス リミテッド 性ホルモン依存性疾患を治療するためのｎｋ−１／ｎｋ−３受容体デュアルアンタゴニスト
FR3056436B1 (fr) * 2016-09-23 2018-11-16 Sidel Participations Fond de moule pourvu de canaux de decompression debouchant sur une face superieure peripherique
US10079583B2 (en) * 2016-11-29 2018-09-18 Taiwan Semiconductor Manufacturing Company, Ltd. Transmitter power detection circuit and method
US10799818B2 (en) * 2017-07-28 2020-10-13 Ruff Equipment, Inc. Gasket for screen frame
EA202090321A1 (ru) * 2017-08-14 2020-09-24 Спрюс Биосайнсес, Инк. Антагонисты рецептора кортикотропин-рилизинг фактора
CN110996943A (zh) 2017-08-14 2020-04-10 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
BR112020024062A2 (pt) 2018-04-27 2021-02-09 Spruce Biosciences, Inc. métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
JP7238130B2 (ja) 2018-12-07 2023-03-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
US20200255436A1 (en) * 2019-02-12 2020-08-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
EP3986416A4 (en) 2019-07-19 2023-06-28 Spruce Biosciences, Inc. Methods of treating congenital adrenal hyperplasia
WO2022036123A1 (en) 2020-08-12 2022-02-17 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
EP4402142A1 (en) 2021-11-19 2024-07-24 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Also Published As

Publication number Publication date
US20230295161A1 (en) 2023-09-21
CN116322544B (zh) 2024-08-02
CA3188730A1 (en) 2022-02-17
WO2022036123A1 (en) 2022-02-17
BR112023002497A2 (pt) 2023-05-02
JP2023537598A (ja) 2023-09-04
KR20240023691A (ko) 2024-02-22
US12098152B2 (en) 2024-09-24
US20230322775A1 (en) 2023-10-12
EP4175572A1 (en) 2023-05-10
KR20230043222A (ko) 2023-03-30
CN116322544A (zh) 2023-06-23
IL300478A (en) 2023-04-01
US11858932B2 (en) 2024-01-02
EP4175572A4 (en) 2024-03-27
AU2021324839A1 (en) 2023-03-02
AU2021324839B2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
MX2023001688A (es) Metodos y composiciones para tratar el sindrome de ovario poliquistico.
MX2008011127A (es) INHIBIDOR DE 17ß HSD TIPO 5.
AU2020271833A8 (en) HMOX1 inducers
Maurino et al. A proof of the direct hole transfer in photocatalysis: the case of melamine
SG11201809744YA (en) Method for improving salt tolerance of plant
Lee et al. In situ spectroscopic studies of the effect of water on the redox cycle of Cu ions in Cu-SSZ-13 during selective catalytic reduction of NO x
RU2532777C1 (ru) Способ комбинированной химико-термической обработки деталей машин из теплостойких сталей
CN107245733A (zh) 一种高强钢低氢脆电镀镉的方法
US2071966A (en) Pickling inhibitor and process
BR112019003271A2 (pt) método para tratar verrugas ou uma condição associada com verruga, método para tratamento de verrugas comuns e kit para tratamento de verrugas
MY136565A (en) Passivation of steel surface to reduce coke formation
Raimondis et al. Histamine lipolytic activity and semicarbazide-sensitive amine oxidase (SSAO) of rat white adipose tissue (WAT)
CN103014578A (zh) 一种热镀锌助镀剂的配方
CN104988543A (zh) 一种环保型无氰碱性镀锌用光亮剂及其制备方法
Jiang et al. Regulating the generation of singlet oxygen (1O2) in Advanced oxidation processes by catalyst design for water treatment
Silva et al. Effect of methane addition on formation of plasma nitrocarburized layers
RU2633427C1 (ru) Композиция для формирования противокоррозионных фосфатных покрытий на стальной поверхности
BR112022006757A2 (pt) Sistemas e métodos para tratar um substrato de metal
Akhatova et al. Antiradical properties of uracil derivatives
Shinkar et al. The Utilization Of Toxic Hydrogen Sulfide For Obtaining Of Thiolation Products Of Bicyclic Hydrocarbons By Its Anodic Activation
Aggarwal et al. Indian manufacturing industry: Verdoorn's law revisited
MX2021004911A (es) Nuevo proceso electroquimico basado en factor adimensional.
Vasudha et al. Studies on inhibition of acid corrosion of mild steel by Terminalia catappa (tropical almond) leaves
WO2019006679A1 (zh) 除油除锈钝化三合一钝化剂、钢铁件及其钝化处理方法
Rijal et al. Nanoscale patterns at molecule/MoS 2 heterostructure and their effects on the interlayer exciton dynamics.